Biologics for the Treatment of Recurrent Respiratory Papillomatosis
- PMID: 34099306
- PMCID: PMC8254746
- DOI: 10.1016/j.otc.2021.05.002
Biologics for the Treatment of Recurrent Respiratory Papillomatosis
Abstract
This article aims to educate readers on adjuvant therapies for recurrent respiratory papillomatosis (RRP). Although antivirals are injected locally into papillomas as an adjuvant treatment, new biologics targeting vascular endothelial growth factor or induction of human papillomavirus (HPV)-specific immunity are gaining traction with demonstration of clinical benefit and mechanism of action in retrospective case series and prospective clinical trials. The future of RRP treatment, alone or in combination with surgery, lies in the careful clinical study of vascular and immune targeting agents that balance the risk of adverse events with the chance for elimination of HPV-infected cells.
Keywords: Bevacizumab; Cidofovir; Immunotherapy; Recurrent respiratory papillomatosis.
Published by Elsevier Inc.
Conflict of interest statement
Disclosure The author declares no conflicts of interest.
References
-
- Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis. Otolaryngol Clin North Am. 2019;52(4):669–679. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
